Paramil Pharma Ltd upgraded FY27 annual guidance to approximately 19% to 20% revenue growth, with EBITDA expected to grow faster than revenue. Q2 revenue grew 28% year-on-year to 2,617 crores, while EBITDA rose 72% to 385 crores.

3 source passages

Paramil Pharma Ltd In Q2, revenue grew by 28% year-on-year to 2,617 crores, while EBITDA increased 72% to 385 crores. Given this broad-based performance and outlook for the second half, we're upgrading our FY27 annual guidance with earlier guidance to early to mid-teens revenue growth with EBITDA to grow faster than revenue. We now expect an annual revenue growth of approximately 19% to 20% with a meaningful higher growth and profitability. Open the document at this passage

Showing 1–1 of 1 documents